Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting.

Salomon, Ran; Rotem, Hagar; Katzenelenbogen, Yonatan; Weiner, Assaf; Cohen Saban, Noy; Feferman, Tali; Amit, Ido; Dahan, Rony

Salomon, Ran; Rotem, Hagar; Katzenelenbogen, Yonatan; Weiner, Assaf; Cohen Saban, Noy; Feferman, Tali; Amit, Ido; Dahan, Rony.

Affiliation

Salomon R; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Rotem H; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Katzenelenbogen Y; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Weiner A; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Cohen Saban N; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Feferman T; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Amit I; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Dahan R; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. rony.dahan@weizmann.ac.il.

Nat Cancer ; 3(3): 287-302, 2022 03.

Article de En | MEDLINE | ID: mdl-35190724

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Anticorps bispécifiques / Tumeurs Limites: Humans Langue: En Journal: Nat Cancer Année: 2022 Type de document: Article Pays d'affiliation: Israël Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google